Despite evidence suggesting there is an impact of physical activity and body mass index on the risk for Parkinson disease, a large prospective study published in Neurology shows that there is no significant association between prolonged sitting/inactivity or obesity with PD risk.
Patients with TBI had a higher incidence of PD compared with patients without TBI.
Using information from these assessments, investigators identified participants as having either major psychotic symptoms, isolated minor psychotic symptoms, or no psychotic symptoms.
Lightning, which can result in strong electromagnetic fields, can interfere with deep brain stimulation devices.
Risk factors for all study participants were calculated on the basis of the following factors known to be previously linked to PD risk: total caffeine intake, smoking, physical activity, and family history of PD.
The assessment of psychiatric symptoms relied on only one question in the MDS-UPDRS, potentially leading to underestimation of these symptoms in this cohort.
Patients with IBD who were exposed to anti-TNF therapy had a significant decrease in incidence of PD.
Non-invasive neuromodulation therapy using a custom stimulation pattern provides symptomatic relief from hand tremor in essential tremor.
Concerns over Nuplazid were initially voiced in a CNN article in early April which reported that the drug had been associated with over 700 deaths since its launch in March 2017.
Previous research has suggested a genetic and functional link between IBD and PD, however evidence regarding this association has been limited.
Mild traumatic brain injury is associated with increased risk of Parkinson disease among military veterans.
By 2 years, 30% of patients had increased their levodopa dose by ~300mg, indicating that treatment with Gocovri may allow for further levodopa optimization despite the occurrence of dyskinesia.
Investigators conducted a review of electronic medical records to assess functional neurologic disorders in patients with Parkinson disease.
Wearable technology may help monitor on/off states in patients with Parkinson disease in an outpatient setting.
Researchers sought to assess outcomes in hospitalized patients with comorbid Parkinson disease and major depressive disorder following administration of deep brain stimulation.
In this article, we explore research findings to provide a deeper understanding of the factors associated with increased risk for impulse control disorders in Parkinson disease. Deputy Director of the Parkinson's UK charity, Professor David Dexter, also provides insights on the mechanisms of impulse control disorders and the implications of new findings on the management of Parkinson disease.
Researchers say that tears may be an inexpensive, reliable, and noninvasive biological marker of Parkinson's disease.
Researchers found that for men with any occupational exposure to diesel exhaust, the odds ratio for amyotrophic lateral sclerosis increased with increasing lag periods.
Approximately 20% of patients in this cohort were considered clinically depressed based on GDS criteria.
Demoralization is common in patients with Parkinson disease and is associated with motor dysfunction.
ADS-5102 is a promising treatment option: if taken once daily at night, it achieves highest plasma drug concentrations throughout the day when symptoms are most bothersome.
Seven patients with progressive supranuclear palsy received bilateral pedunculopontine nucleus deep brain stimulation at frequencies of 8, 20, 60, and 130 Hz.
Pseudobulbar affect is characterized by episodes of inappropriate laughing or crying, and may be associated with increased anxiety and depression, as well as lower mental health status.
Although deep brain stimulation, similar to all Parkinson disease therapies, cannot cure, modify, or slow progression of the disease, some recent research suggests that the symptom alleviation and quality-of-life improvement it provides might lead to mild improvements in longevity.
The office-based, eight-item Montreal Parkinson Risk of Dementia Scale is a valid predictor of development of dementia.
"Since the current generation of psychiatrists has been raised on second-generation antipsychotics and has relatively little experience with first-generation antipsychotics, keeping tardive dyskinesia in mind is not, on the whole, part of their experience or training," said Christoph U. Correll, MD.
Patients who received 100 mg/day riluzole spent significantly more time in stage 4 than patients who were randomly assigned to placebo.
Sunovion announced the submission of its New Drug Application for apomorphine sublingual film for OFF episodes linked with PD.
Idiopathic Parkinson disease is independently associated with an increased risk for overactive bladder.
Parkinsonism syndromes are associated with progressive disability and increased mortality, with symptom burden comparable to that of advanced cancer.
Neurology Advisor Articles
- FDA Approves Aimovig for Migraine Prevention
- Psychological Therapies May Help Older Adults With Chronic Pain
- Vitamin D: The Only Dietary Supplement Showing Significant Benefit for MS
- Concussion Misdiagnosis Associated With Emergency Department Stay, Injury Type
- Evolution of NEDA: Q&A With Cleveland Clinic's Dr Robert Bermel
- Micronutrient Levels May Be Altered in ADHD
- FDA Approves Aimovig for Migraine Prevention
- Solriamfetol Associated With Improvement in Narcolepsy Types 1 and 2
- Sports-Related Concussion Outcomes Predicted With Serum Neurofilament Light
- FDA: Lamotrigine Linked to Potentially Life-Threatening Adverse Reaction
- Low Income, Singlehood, and Race Tied to Seizure Control in Active Epilepsy
- FNIH Launches Project to Identify Biosignatures of Neurodegenerative, Psychiatric Conditions
- Associations Between Maternal Depression, Support, and Cognitive Development in Offspring
- Alteplase Good for Ischemic Stroke With Unknown Onset Time
- Aerobic and Strength Exercise Doesn't Slow Cognitive Decline